APSR2026-817

 
Regular
Submitted
Oral Presentation
AO32-001
 
 
 
Format: PPTX Only
 
Format: PDF Only
05. Respiratory Infections (non-tuberculous)
4

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Nurgul Naurzvai - Atakent Acibadem University Hospital Pulmonary Medicine Istanbul Turkiye
Verda Tuna Dinar - Atakent Acibadem University Hospital Intensive Care Unit Istanbul Turkiye
Solongo Bandi * School of Medicine Mongolian National University of Medical Sciences Pulmonary Medicine Ulanbator Turkiye
Iftahar Koksal - Atakent Acibadem University Hospital Infectious Diseases Istanbul Turkiye
-
-
-
-
-
-
-
-
-
-
-
Presenting Author Details
Solongo
Bandi
solongo.b@mnums.edu.mn
+97688887914
51-60
Mongolia
Original Research
Cytomegalovirus DNA in lower respiratory tract samples: Influence of intensive care unit admission and sampling method in immunocompromised patients
Maximum 25 words
Abstract Content
<p>Cytomegalovirus (CMV) reactivation is increasingly recognized among critically ill and immunocompromised patients. However, the clinical relevance of CMV DNA detected in lower respiratory tract specimens remains controversial, particularly in differentiating true CMV pneumonitis.</p>
<p>We conducted a retrospective cohort study (2019–2024) including 419 lower respiratory tract samples analyzed for CMV DNA using polymerase chain reaction (PCR). The study population comprised patients with hematological malignancies, solid organ transplantation, and liver failure. Samples were stratified by clinical setting (intensive care unit [ICU] vs. ward) and sampling modality (bronchoalveolar lavage [BAL] vs. transtracheal aspirate [TA]). CMV positivity rates and viral load distributions were compared. Multivariable logistic regression analysis was performed to identify independent predictors of CMV DNA positivity.</p>
<p>CMV DNA was detected in 58.2% of samples (244/419), with higher detection rates observed among ICU patients and in tracheal aspirate (TA) specimens. Baseline demographic characteristics were similar between CMV positive and CMV negative groups, including median age (62 vs. 58 years, p=0.08) and comorbidity burden (66.4% vs. 65.7%). Although BAL samples demonstrated lower overall positivity rates, they were associated with significantly higher median viral loads, particularly among ICU patients. ICU admission was associated with increased odds of CMV DNA detection (OR 1.39, 95% CI 0.70–2.74), whereas BAL sampling showed a trend toward reduced positivity (OR 0.60, 95% CI 0.34–1.07). Notably, while the majority of positive samples exhibited low to moderate viral loads, a subset predominantly ICU BAL specimens exceeded 10⁴ copies/mL, suggestive of clinically significant pulmonary involvement.</p>
<p>CMV DNA is frequently identified in lower respiratory tract specimens from immunocompromised individuals, with detection rates highest among patients in ICU and in TA samples. The markedly elevated viral loads observed in BAL specimens may be more indicative of active pulmonary CMV infection, whereas lower level detection in TA samples may represent asymptomatic viral shedding or subclinical reactivation. The predominance of TA sampling in critically ill cohorts likely reflects the procedural challenges and increased risk associated with performing BAL in patients with significant respiratory compromise.</p>
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Cytomegalovirus, Immunocompromised patients, Tracheal aspirate, Bronchoalveolar lavage
maximum 3 keywords and no abbreviations, separated by commas
I have no disclosure.
343